Mylan and Biocon's Trastuzumab Biosimilar Gains European Marketing Authorization
December 19th 2018
By The Center for Biosimilars Staff
ArticleMylan and Biocon have received final approval from the European Commission to market their trastuzumab biosimilar, Ogivri, referencing Herceptin.